XRCC6P5 and neoplasm: Whereas many molecular determinants of radiosensitivity have been identified, such as DNA repair proteins and those involved in cell cycle checkpoint activation, the development of clinically relevant radiosensitizers requires the identification of proteins that preferentially influence the radioresponse of tumor cells.